Plain-English translation of NCT07139977 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a medication called in women whose endometrial cancer has come back or worsened after chemotherapy and immunotherapy. The medication works by targeting a specific protein found on cancer cells. Researchers want to see if this treatment can slow or stop cancer growth and how safe it is.
Endometrial cancer that returns after standard treatments is very difficult to treat, and many patients don't have good options left. This medication targets cancer cells in a new way, offering hope for patients whose cancer has already progressed through other therapies.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the medication on days 1, 8, and 15 of each 28-day cycle, continuing for up to 12 months or until your cancer worsens, side effects become too severe, or you choose to stop. Throughout the study, you'll have regular blood tests and imaging scans (CT or MRI) to monitor how well the treatment is working and check for side effects. If your cancer remains stable or improves, you may continue on the medication; if it progresses, you'll be followed to track your health status.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
William Bradley
Collaborators
Astellas Pharma Inc
Enrollment target
~12 participants
Started
July 2026
Primary completion
November 2027
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mastaneh Irani
Medical College of Wiscnson
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.